the bva-100 (blood volume analyzer) is the first instrument of its kind that can precisely measure the amount of blood a patient has in their body. blood volume measurements have been available for almost 60 years, but the test often took 4 to 8 hours to perform and was very difficult to perform accurately. due to these issues, blood volume measurements were very rarely done. physicians had been forced to rely on substitute tests that were only able to measure the thickness of the blood and can be very misleading in many surgical and medical situations. the bva-100 can measure blood volume: accurately, quickly & reliably.
Company profile
Ticker
DXR
Exchange
Website
CEO
Michael R. Feldschuh
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
132682108
DXR stock data
Analyst ratings and price targets
Latest filings (excl ownership)
N-PX
Annual report of proxy voting record
9 Sep 24
N-CSRS
Certified semi-annual shareholder report (management investment company)
29 Aug 24
8-K
Submission of Matters to a Vote of Security Holders
18 Jul 24
DEF 14A
Definitive proxy
21 Jun 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5 Jun 24
8-K
Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics
25 Mar 24
N-CSR/A
Certified annual shareholder report (management investment company) (amended)
19 Mar 24
N-CEN
Annual report (registered investment company)
15 Mar 24
N-CSR
Certified annual shareholder report (management investment company)
15 Mar 24
NT-NCSR/A
Notice of inability to timely file Form N-CSR (amended)
8 Mar 24
Transcripts
Latest ownership filings
Institutional ownership, Q2 2024
0.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 1 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 241.97 mm |
Total shares | 25.96 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Renaissance Technologies | 15.12 k | $140.93 mm |
Keyes, Stange & Wooten Wealth Management | 10.84 k | $101.04 mm |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Jul 24 | Henry D. Cremisi | Stock Options COMMON STOCK | Grant | Acquire A | No | No | 9.2 | 2,500 | 23.00 k | 2,500 |
15 Jul 24 | Edward Feuer | Stock Options COMMON STOCK | Grant | Acquire A | No | No | 9.2 | 2,500 | 23.00 k | 2,500 |
15 Jul 24 | Joy S. Goudie | Stock Options COMMON STOCK | Grant | Acquire A | No | No | 9.2 | 2,500 | 23.00 k | 2,500 |
15 Jul 24 | Caleb DesRosiers | Stock options Common Stock | Grant | Acquire A | No | No | 9.2 | 2,500 | 23.00 k | 2,500 |
27 Mar 24 | Robert J Michel | Daxor Common Stock | Buy | Acquire P | No | No | 8.7 | 750 | 6.53 k | 11,300 |
News
Ascendiant Capital Maintains Buy on Daxor, Raises Price Target to $24.75
9 Sep 24
Daxor Receives $300K Matching Fund Award From Launch Tennessee To Will Drive Innovation, Commercialization Efforts, And Job Creation
5 Sep 24
Daxor Corporation CEO Michael Feldschuh Delivers Mid-Year Corporate Update, Reports Significant Financial Growth, Secures New Government Contracts, And Announces Strategic Acquisitions In Shareholder Letter
3 Sep 24
Press releases
DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24
9 Oct 24
Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device
27 Sep 24
Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024
19 Sep 24
Leading Central Florida Hospital Implements Daxor's BVA-100™ Blood Volume Diagnostic for Heart Failure Patient Care
4 Sep 24
Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter
3 Sep 24